Expert perspectives on cholangiocarcinoma (CCA)

When could “cancer of unknown primary” be CCA? (ESMO 2021)

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

CCA: under the spotlight (2021)

This online webinar took place on 26 February 2021 and was hosted by our esteemed faculty who critically discussed the complexity of diagnosing CCA and the clinical and genetic heterogeneity associated with the disease

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Dr Coralie Sayag

Former Medical Director Solid Tumours,
Region Europe, Incyte Biosciences International Sàrl (01 May 2020 – 31 May 2022)

Perspectives on precision medicine in CCA (2021)

Listen to Professor Eric Van Cutsem and Dr Angela Lamarca provide expert perspectives on key questions in precision medicine and molecular testing in advanced CCA

Professor Eric Van Cutsem

University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Optimising the multidisciplinary team for CCA management (ESMO 2021)

Dr David Malka

Institut Mutuaslite Montsouris, France

Overview of CCA (ILCA 2020)

Professor Bruno Sangro

Director, Liver Unit & Co-Director, HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain

Unmet needs in CCA (ESMO 2020)

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Dr Nicola Normanno

Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy

Importance of molecular profiling in patients with CCA (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

Importance of biomarkers in CCA (ESMO GI 2021)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Importance of performing biopsies in patients with CCA (ESMO 2020)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and Humanitas Research Hospital-IRCCS, Milan, Italy

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Peter Schirmacher

Institute of Pathology, University Hospital Heidelberg

I see CCA today (2022)

World CCA Day (12 February 2022), organised by the Global CCA Alliance, is an international effort to raise awareness of CCA. The purpose of Rare Disease Day (28 February 2022) is to raise awareness and generate change for the 300 million people worldwide living with a rare disease.¹ To support these initiatives, we asked a patient with CCA and a multidisciplinary panel of CCA experts to express how they #SeeCCA today.

Reference: 1. Nguengang Wakap S, et al. Eur J Hum Genet. 2020;28:165–73.

Helen Morement

CEO and Founder of AMMF - The Cholangiocarcinoma Charity, London, UK

Phil Preston

Patient,
UK

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Dr Joachim Mertens

University Hospital Zürich,
Zürich, Switzerland

Professor Juan Valle

The Christie NHS Foundation Trust and
University of Manchester, UK

Professor Thomas Gruenberger

Sigmund Freud University,
Vienna, Austria

Professor Bruno Sangro

Director, Liver Unit & Co-Director, HPB Oncology Area, Clinica Universidad de Navarra, Pamplona, Spain

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Glenda O’Connor

The Wellington Hospital,
London, UK

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel Grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Company/Organisation	Relationship(s)
Personal financial interests:
Ability Pharmaceuticals SL, Aptitude Health, AstraZeneca, Basilea Pharma, Baxter, BioLineRX Ltd, Celgene, Eisai, Ellipses, Genzyme, Got It Consulting SL, Hirslanden/GITZ, Imedex, Incyte, Ipsen Bioscience, Inc, Janssen, Lilly, Marketing Farmacéutico & Investigación Clínica, S.L, MDS, Medscape, Novocure, Paraxel, PPD Development, Polaris, QED Therapeutics, Roche Farma, Sanofi-Aventis, Servier, Scilink Comunicación Científica SC, Surface Oncology, Swedish Orpahn Biovitrum AB, Zymeworks	Advisory role Speaker’s fee Direct research fund
Institutional financial interests:
AbbVie Farmaceútica, Ability Pharmaceuticals, Agios Pharmaceuticals, Amc Medical Research, Amgen, Armo Biosciences, Aslan Pharmaceuticals, Astrazeneca, Basilea Pharmaceutica International, Bayer, Beigene, Biokeralty Research Institute, Biolinerx, Blueprint Medicines, Boston Biomedical, Bristol-Myers Squibb (BMS), Cantargia, Celgene, Eisai, Erytech Pharma, F. Hoffmann-la Roche, Fibrogen, Halozyme, Incyte, Ipsen Bioscience, Ipsen Pharma, Lilly, Loxo Oncology, Medimmune, Merck Sharp & Dohme, Nelum, Novartis, Novocure, Oncomed Pharmaceuticals, QED Therapeutics, VCN Biosciences, Zymeworks	Clinical trial support

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier	Consulting honoraria
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier	Speaker honoraria
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical	Travel, education funding

Company/Organisation	Relationship(s)
Incyte	Consultant
Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier	Research grants
Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, Taiho	Advisory boards

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boston Scientific, EISAI, Ipsen, QED, Nutricia, Roche, Servier	Consulting honoraria
AAA pharmaceuticals, AstraZeneca, EISAI, Incyte, Ipsen, QED, Merck, Pfizer, Servier	Speaker honoraria
AAA pharmaceutical, Bayer, Delcath Systems, Ipsen, Mylan, Novartis, Pfizer, Sirtex Medical	Travel, education funding

Expert perspectives on cholangiocarcinoma (CCA)

When could “cancer of unknown primary” be CCA? (ESMO 2021)

CCA: under the spotlight (2021)

Perspectives on precision medicine in CCA (2021)

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Optimising the multidisciplinary team for CCA management (ESMO 2021)

Overview of CCA (ILCA 2020)

Unmet needs in CCA (ESMO 2020)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Importance of molecular profiling in patients with CCA (ESMO 2020)

Importance of biomarkers in CCA (ESMO GI 2021)

Importance of performing biopsies in patients with CCA (ESMO 2020)

I see CCA today (2022)

All videos in this category

When could “cancer of unknown primary” be CCA? (ESMO 2021)

CCA: under the spotlight (2021)

Perspectives on precision medicine in CCA (2021)

Importance of the multidisciplinary team in CCA diagnosis and treatment (ESMO 2020)

Optimising the multidisciplinary team for CCA management (ESMO 2021)

Overview of CCA (ILCA 2020)

Unmet needs in CCA (ESMO 2020)

Detecting FGFR2 fusions in patients with CCA (ESMO GI 2021)

Importance of molecular profiling in patients with CCA (ESMO 2020)

Importance of biomarkers in CCA (ESMO GI 2021)

Importance of performing biopsies in patients with CCA (ESMO 2020)

I see CCA today (2022)

Enhance your CCA knowledge with Incyteful

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Nerviano Medical Sciences, Roche, Sanofi	Consulting/Advisory role
AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi	Honoraria/Lectures
Ipsen	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Roche	Research funding to institution

Company/Organisation	Relationship(s)
AstraZeneca, Incyte, Janssen, Novartis, Roche	Speakers bureau
Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Janssen, Merck Sharp & Dohme, Novartis, Roche	Board
AstraZeneca, Bristol Myers Squibb, Illumina, Novartis	Grant support

Company/Organisation	Relationship(s)
Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Exelixis, Ipsen, Lilly, Merck, Novartis, Roche, Sirtex Medical, Terumo	Consulting, advisory role or honoraria
Bristol Myers Squibb, Sirtex Medical	Grants

Company/Organisation	Relationship(s)
MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly	Personal financial interests (speaker’s fee and/or advisory boards)
Merck, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina	Institutional financial interests (financial support to research projects)
President, International Quality Network for Pathology (IQN Path); President, Italian Cancer Society (SIC)	Non-financial interests

Company/Organisation	Relationship(s)
Bayer, Bristol Myers Squibb, Guardant Health, Incyte, Merck, Novartis, Roche	Advisory board
Sysmex	Consultant